Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Artivion, Inc. (NYSE: AORT), a medical device company focused on cardiac and vascular surgery and the treatment of aortic diseases. Through these filings, investors can review Artivion’s detailed financial statements, risk disclosures, material agreements and governance information.
Artivion’s periodic reports on Forms 10-K and 10-Q describe its business, which includes aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, as well as preservation services for cardiac and vascular tissues. These filings outline segment-level information, geographic reach and key risk factors associated with its aortic-focused product portfolio and international operations.
Current reports on Form 8-K document material events such as quarterly financial results, amendments to the company’s credit and guaranty agreement, real estate purchase contracts for manufacturing and office facilities, and executive leadership changes. For example, recent 8-K filings discuss an amendment that extended the maturity of term loan and revolving credit facilities and added a secured delayed draw term loan facility, as well as agreements to purchase properties supporting On-X manufacturing operations in Austin, Texas.
On Stock Titan, Artivion’s SEC filings are updated in near real time as they are posted to EDGAR. AI-powered summaries help explain complex sections of lengthy documents, such as credit agreement amendments, non-GAAP reconciliations, and detailed risk factor discussions. Investors can quickly locate annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K), and use AI-generated highlights to understand how new filings may relate to Artivion’s aortic device portfolio, clinical programs, capital structure and corporate strategy.
Artivion Inc. received an updated Schedule 13G/A (Amendment No. 7) from Macquarie Group Limited, Macquarie Management Holdings Inc., and Macquarie Investment Management Business Trust regarding Artivion’s common shares. As of 12/31/2025, the Macquarie reporting entities disclose beneficial ownership of 0 common shares, representing 0.00% of the class, with no sole or shared voting or dispositive power. The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Artivion.
Artivion, Inc. reported strong growth for the fourth quarter and full year 2025, moving from losses to profitability. Fourth quarter GAAP revenue rose to $116.0 million from $97.3 million, with GAAP net income of $2.4 million versus a prior-year net loss of $(16.5) million. Full year 2025 revenue increased to $441.3 million from $388.5 million, and GAAP net income improved to $9.8 million from a net loss of $(13.4) million. Non-GAAP net income reached $8.6 million in the quarter and $29.7 million for the year, while adjusted EBITDA grew to $22.7 million in the quarter and $89.6 million for 2025. Growth was driven by aortic stent grafts, On-X valves, and steady preservation services, supported by positive clinical data and progress on regulatory filings. For 2026, Artivion guides to revenue of $486–$504 million and adjusted EBITDA of $105–$110 million, implying double‑digit revenue growth and faster adjusted EBITDA growth.
Artivion, Inc.'s Chief Commercial Officer reported selling company stock in an insider transaction. On 12/15/2025, John E. Davis sold 5,000 shares of Artivion common stock at $45.11 per share, as reflected in a regulatory report.
After this sale, Davis beneficially owned 193,842 Artivion shares, all held directly. The report was filed by him as a single reporting person in his role as Chief Commercial Officer.
John E. Davis submitted a notice of proposed sale of 5000 shares of the issuer’s common stock through broker Charles Schwab, with an approximate sale date of 12/15/2025. The shares have an aggregate market value of 225553.67 as reported in the notice and are listed on the NYSE.
The notice states that 47374939 common shares were outstanding, which helps put the planned sale in context. Davis originally acquired 10000 common shares from the issuer in a purchase on 09/16/2020, with payment made on the same date. By signing, the seller represents that he is not aware of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.
Artivion, Inc. insider Form 4 details a routine tax-related stock sale. The company’s Vice President and Chief Accounting Officer reported selling 4,572 shares of Artivion common stock on 12/08/2025 at a price of $44.419 per share. After this transaction, the officer beneficially owned 130,058 shares directly.
The filing explains that the shares were sold automatically upon the vesting of restricted stock units to cover tax withholding obligations through a “sell to cover” transaction, meaning it was not a discretionary open-market trade by the insider.
An AORT shareholder filed a Rule 144 notice to sell up to 4,572 shares of common stock through Fidelity Brokerage Services on the NYSE around 12/08/2025. The filing lists an aggregate market value of $203,081.38 for this planned sale, compared with 47,374,939 common shares outstanding for the issuer. The seller acquired these 4,572 shares as restricted stock vesting from the issuer on 12/05/2025, treated as compensation.
Over the prior three months, the same seller reported additional open-market sales of the issuer’s common stock: 1,789 shares on 11/10/2025 for $79,823.21, 3,482 shares on 11/13/2025 for $159,678.60, and 6,000 shares on 11/17/2025 for $274,382.11. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
Artivion, Inc. reported an insider stock transaction by its President & CEO, James P. Mackin. On December 3, 2025, he exercised stock options to acquire 30,921 shares of Artivion common stock at an exercise price of $29.62 per share, then sold the same 30,921 shares in the open market at a weighted average price of approximately $45.461 per share.
The option exercise and sale were conducted under a Rule 10b5-1 trading plan adopted on September 2, 2025. After these transactions, he directly owns 800,993 shares of Artivion common stock. The reported stock option, originally granted on March 5, 2020 with an expiration date of March 5, 2026, is now fully exercised and shows 0 options remaining.
Artivion, Inc. executive Jean F. Holloway, the company’s SVP and General Counsel, reported open-market sales of company stock. On 12/03/2025, she sold 2,048 shares of Artivion common stock at a price of $45.3 per share and, in a separate transaction the same day, sold an additional 5,267 shares at $45.3 per share.
Following these transactions, Holloway beneficially owns 156,093 shares of Artivion common stock directly. The filing is a standard Form 4 disclosure of insider trading activity required for company officers.
Artivion, Inc. (AORT) reported an insider stock transaction by its President & CEO. On 12/02/2025, the executive exercised stock options to buy 30,921 shares of common stock at an exercise price of $29.62 per share and then sold 30,921 shares of common stock in a separate transaction at a weighted average price of $45.559 per share.
The transactions were executed under a Rule 10b5-1 trading plan adopted on September 2, 2025. Following these moves, the reporting person held 800,993 shares of Artivion common stock in direct ownership.
James Mackin filed a Form 144 notice to sell 30,921 common shares of the issuer through Fidelity Brokerage Services LLC on the NYSE, with 47,374,939 shares outstanding. The shares relate to an option originally granted on 03/05/2019 and acquired on 12/03/2025, with the purchase price paid in cash on the same date. In the past three months, Mackin has sold additional common shares in three transactions, totaling 17,580 shares for gross proceeds of $784,400.26, 34,210 shares for $1,568,812.44, and 30,921 shares for $1,408,736.02. By signing the notice, the seller represents that he is not aware of any undisclosed material adverse information about the issuer’s operations.
FAQ
What is the current stock price of Artivion (AORT)?
What is the market cap of Artivion (AORT)?
